U.S. Food and Drug Administration Financial Analyst Salaries in Gulfport-Biloxi, MS
The average U.S. Food and Drug Administration Financial Analyst in Gulfport-Biloxi, MS earns an estimated $90,316 annually, which includes an estimated base salary of $78,565 with a $11,752 bonus. U.S. Food and Drug Administration's Financial Analyst compensation is $2,908 more than the US average for a Financial Analyst. Financial Analyst salaries at U.S. Food and Drug Administration in Gulfport-Biloxi, MS can range from $31,500 - $310,000.
In Gulfport-Biloxi, MS, The Finance Department at U.S. Food and Drug Administration earns $18,181 more on average than the Customer Support Department.
Last updated 3 years ago.
- $78,565
- avg. base
- $11,752
- avg. bonus
Financial Analyst Salaries at U.S. Food and Drug Administration
In Gulfport-Biloxi, MS, Financial Analysts earn $446 more than Business Analysts, and $2,229 less than Senior Accountants.
Compensation at U.S. Food and Drug Administration by Department
In Gulfport-Biloxi, MS, The Finance Department averages $18,181 more than the Customer Support Department, and $9,718 less than the Operations Department
Financial Analyst Compensation by Gender (All Companies)
The average female Financial Analyst at companies similar size to U.S. Food and Drug Administration reported making $93,556, while the average male Financial Analyst at similar sized companies reported making $91,853.
Financial Analyst Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Financial Analyst at companies similar size to U.S. Food and Drug Administration reported making $98,729, while the average Native American Financial Analyst at similar sized companies reported making $60,000.
How Financial Analysts at U.S. Food and Drug Administration Rate Their Compensation
The majority of Financial Analysts at U.S. Food and Drug Administration believe they're compensated fairly. 100% of Financial Analysts at U.S. Food and Drug Administration say they receive annual bonuses, and the vast majority (71%) are satisfied with their benefits. See more compensation ratings at U.S. Food and Drug Administration
